Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland · Delayed Price · Currency is CHF 8.10
-0.08 (-0.98%)
Oct 2, 2026, 2:35 PM CET
Newron Pharmaceuticals Ratios and Metrics
Market cap in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 174 | 476 | 174 | 88 | 28 | 29 | |
Market Cap Growth | -19.56% | 173.36% | 97.16% | 219.36% | -4.32% | -24.65% |
Enterprise Value | 179 | 485 | 209 | 118 | 44 | 34 |
Last Close Price | 8.18 | 23.85 | 8.95 | 4.95 | 1.55 | 1.62 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 11.72 | - | - | - |
Forward PE | - | 39.84 | 10.63 | 95.29 | 7.84 | 39.74 |
PS Ratio | 18.07 | 26.74 | 3.61 | 10.48 | 4.59 | 4.84 |
PB Ratio | -16.11 | -45.92 | 127.32 | -3.17 | -1.99 | 8.98 |
P/TBV Ratio | - | - | 127.32 | - | - | 8.98 |
P/FCF Ratio | - | 15.83 | - | - | - | - |
P/OCF Ratio | - | 15.81 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 18.66 | 27.23 | 4.34 | 13.95 | 7.26 | 5.77 |
EV/EBITDA Ratio | - | - | 8.52 | - | - | - |
EV/EBIT Ratio | - | - | 8.53 | - | - | - |
EV/FCF Ratio | - | 16.12 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | -3.34 | -3.43 | 34.62 | -1.62 | -3.25 | 13.87 |
Debt / EBITDA Ratio | - | - | 1.91 | - | - | - |
Debt / FCF Ratio | - | 1.18 | - | - | - | - |
Net Debt / Equity Ratio | -0.53 | -0.83 | 27.88 | -1.20 | -1.63 | 2.73 |
Net Debt / EBITDA Ratio | -0.27 | -1.99 | 1.55 | -3.12 | -1.72 | -0.69 |
Net Debt / FCF Ratio | -0.52 | 0.29 | -2.31 | -3.53 | -2.06 | -0.74 |
Asset Turnover | 0.21 | 0.37 | 1.15 | 0.29 | 0.14 | 0.11 |
Quick Ratio | 2.89 | 0.70 | 2.42 | 0.62 | 5.50 | 10.58 |
Current Ratio | 3.15 | 0.76 | 2.60 | 0.68 | 5.65 | 10.79 |
Return on Equity (ROE) | - | - | - | - | - | -146.43% |
Return on Assets (ROA) | -27.83% | -5.65% | 36.44% | -23.05% | -18.96% | -15.19% |
Return on Invested Capital (ROIC) | -81.54% | -29.33% | 99.29% | -79.94% | -60.81% | -103.26% |
Return on Capital Employed (ROCE) | -81.50% | 46.60% | 64.80% | 380.00% | -41.40% | -26.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -15.69% | -2.59% | 8.54% | -17.09% | -62.50% | -53.44% |
FCF Yield | -6.27% | 6.32% | -9.50% | -10.70% | -39.69% | -41.12% |
Buyback Yield / Dilution | 4.83% | 2.98% | -15.30% | - | - | - |